Fragile X Syndrome-Pipeline Review, H1 2017

Fragile X Syndrome-Pipeline Review, H1 2017


  • Products Id :- GMDHC9182IDB
  • |
  • Pages: 108
  • |
  • |
  • |
  Request for Sample Report
  Request A Quote

Executive Summary

Fragile X Syndrome-Pipeline Review, H1 2017

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Fragile X Syndrome-Pipeline Review, H1 2017, provides an overview of the Fragile X Syndrome (Genetic Disorders) pipeline landscape.

Gastric ulcer is a painful sore or ulcer in the lining of stomach. The most common cause of gastric ulcer is Helicobacter pylori bacterial infection. Symptoms include pain, bloating, retching, nausea or vomiting and unexplained weight loss. Predisposing factors include smoking and alcoholism. Treatment includes antibiotics and antacids.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Fragile X Syndrome-Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Fragile X Syndrome (Genetic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Fragile X Syndrome (Genetic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Fragile X Syndrome and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 3, 3, 13 and 1 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 3 and 2 molecules, respectively.

Fragile X Syndrome (Genetic Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

The pipeline guide provides a snapshot of the global therapeutic landscape of Fragile X Syndrome (Genetic Disorders).

The pipeline guide reviews pipeline therapeutics for Fragile X Syndrome (Genetic Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.

The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

The pipeline guide reviews key companies involved in Fragile X Syndrome (Genetic Disorders) therapeutics and enlists all their major and minor projects.

The pipeline guide evaluates Fragile X Syndrome (Genetic Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

The pipeline guide reviews latest news related to pipeline therapeutics for Fragile X Syndrome (Genetic Disorders)

Reasons to Buy

Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

Find and recognize significant and varied types of therapeutics under development for Fragile X Syndrome (Genetic Disorders).

Classify potential new clients or partners in the target demographic.

Develop tactical initiatives by understanding the focus areas of leading companies.

Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

Formulate corrective measures for pipeline projects by understanding Fragile X Syndrome (Genetic Disorders) pipeline depth and focus of Indication therapeutics.

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.



Read More



Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications

+91-9015378249

Table of Contents

Table of Contents 2

List of Tables 4

List of Figures 4

Introduction 5

Global Markets Direct Report Coverage 5

Fragile X Syndrome-Overview 6

Fragile X Syndrome-Therapeutics Development 7

Pipeline Overview 7

Pipeline by Companies 8

Pipeline by Universities/Institutes 10

Products under Development by Companies 11

Products under Development by Universities/Institutes 13

Fragile X Syndrome-Therapeutics Assessment 14

Assessment by Target 14

Assessment by Mechanism of Action 16

Assessment by Route of Administration 18

Assessment by Molecule Type 20

Fragile X Syndrome-Companies Involved in Therapeutics Development 22

Aelis Farma SAS 22

AMO Pharma Ltd 22

Anavex Life Sciences Corp 23

Confluence Pharmaceuticals LLC 23

DRI Biosciences Corp 24

Eli Lilly and Company 24

Fulcrum Therapeutics Inc 25

GlaxoSmithKline Plc 25

GW Pharmaceuticals Plc 26

Marinus Pharmaceuticals Inc 26

Neuren Pharmaceuticals Ltd 27

Neuron Biopharma SA 27

Ovid Therapeutics Inc 28

Sage Therapeutics Inc 28

Zynerba Pharmaceuticals Inc 29

Fragile X Syndrome-Drug Profiles 30

acamprosate calcium-Drug Profile 30

ACT-01-Drug Profile 31

AMO-01-Drug Profile 32

ANAVEX-273-Drug Profile 34

Bryostatin-1-Drug Profile 44

cannabidiol-Drug Profile 49

cercosporamide-Drug Profile 54

Drug to Antagonize mGluR5 for Fragile X Syndrome and 16p11.2 Microdeletion Syndrome-Drug Profile 56

flindokalner-Drug Profile 57

gaboxadol-Drug Profile 58

ganaxolone-Drug Profile 60

JRP-655-Drug Profile 67

NNZ-2591-Drug Profile 68

NST-0076-Drug Profile 70

SAGE-217-Drug Profile 71

SGE-872-Drug Profile 74

Small Molecule for Fragile X-Associated Tremor Ataxia Syndrome-Drug Profile 75

Small Molecule to Activate FMRP for Fragile X Syndrome-Drug Profile 76

Small Molecule to Antagonize CB1R for Fragile X Syndrome and Down Syndrome-Drug Profile 77

Small Molecules to Activate Slack Channels for Fragile X Syndrome-Drug Profile 78

Small Molecules to Agonize Cannabinoid Receptor 2 for Fragile X Syndrome, Pervasive Developmental Disorder and Rett Syndrome-Drug Profile 79

Small Molecules to Block Kv3.1 for Fragile X Syndrome-Drug Profile 80

Small Molecules to Inhibit PI3K for Autism and Fragile X Syndrome-Drug Profile 81

SRT-278-Drug Profile 82

TC-2153-Drug Profile 83

trofinetide-Drug Profile 84

Fragile X Syndrome-Dormant Projects 92

Fragile X Syndrome-Discontinued Products 94

Fragile X Syndrome-Product Development Milestones 95

Featured News & Press Releases 95

Appendix 105

Methodology 105

Coverage 105

Secondary Research 105

Primary Research 105

Expert Panel Validation 105

Contact Us 105

Disclaimer 106

List of Figures

Number of Products under Development for Fragile X Syndrome, H1 2017

Number of Products under Development by Companies, H1 2017

Number of Products under Development by Universities/Institutes, H1 2017

Number of Products by Top 10 Targets, H1 2017

Number of Products by Stage and Top 10 Targets, H1 2017

Number of Products by Top 10 Mechanism of Actions, H1 2017

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2017

Number of Products by Routes of Administration, H1 2017

Number of Products by Stage and Routes of Administration, H1 2017

Number of Products by Molecule Types, H1 2017

Number of Products by Stage and Molecule Types, H1 2017

List of Tables

Number of Products under Development for Fragile X Syndrome, H1 2017

Number of Products under Development by Companies, H1 2017

Number of Products under Development by Universities/Institutes, H1 2017

Products under Development by Companies, H1 2017

Products under Development by Companies, H1 2017 (Contd..1), H1 2017

Products under Development by Universities/Institutes, H1 2017

Number of Products by Stage and Target, H1 2017

Number of Products by Stage and Mechanism of Action, H1 2017

Number of Products by Stage and Route of Administration, H1 2017

Number of Products by Stage and Molecule Type, H1 2017

Fragile X Syndrome-Pipeline by Aelis Farma SAS, H1 2017

Fragile X Syndrome-Pipeline by AMO Pharma Ltd, H1 2017

Fragile X Syndrome-Pipeline by Anavex Life Sciences Corp, H1 2017

Fragile X Syndrome-Pipeline by Confluence Pharmaceuticals LLC, H1 2017

Fragile X Syndrome-Pipeline by DRI Biosciences Corp, H1 2017

Fragile X Syndrome-Pipeline by Eli Lilly and Company, H1 2017

Fragile X Syndrome-Pipeline by Fulcrum Therapeutics Inc, H1 2017

Fragile X Syndrome-Pipeline by GlaxoSmithKline Plc, H1 2017

Fragile X Syndrome-Pipeline by GW Pharmaceuticals Plc, H1 2017

Fragile X Syndrome-Pipeline by Marinus Pharmaceuticals Inc, H1 2017

Fragile X Syndrome-Pipeline by Neuren Pharmaceuticals Ltd, H1 2017

Fragile X Syndrome-Pipeline by Neuron Biopharma SA, H1 2017

Fragile X Syndrome-Pipeline by Ovid Therapeutics Inc, H1 2017

Fragile X Syndrome-Pipeline by Sage Therapeutics Inc, H1 2017

Fragile X Syndrome-Pipeline by Zynerba Pharmaceuticals Inc, H1 2017

Fragile X Syndrome-Dormant Projects, H1 2017

Fragile X Syndrome-Dormant Projects, H1 2017 (Contd..1), H1 2017

Fragile X Syndrome-Discontinued Products, H1 2017

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@] kenresearch.com
 

Aelis Farma SAS, AMO Pharma Ltd, Anavex Life Sciences Corp, Confluence Pharmaceuticals LLC, DRI Biosciences Corp, Eli Lilly and Company, Fulcrum Therapeutics Inc, GlaxoSmithKline Plc, GW Pharmaceuticals Plc, Marinus Pharmaceuticals Inc, Neuren Pharmaceuticals Ltd, Neuron Biopharma SA, Ovid Therapeutics Inc, Sage Therapeutics Inc, Zynerba Pharmaceuticals Inc

select a license

Single User License
USD 2000 INR 128520
Site License
USD 4000 INR 257040
Corporate User License
USD 6000 INR 385560

NEWSLETTER BY CATEGORY




Testimonials

The report sent to us was on the point, and its information was quite extensive, well structured, and well researched. More importantly what we valued was your response time and professionalism. As a leading global consulting firm, our clients expect high quality deliverables in short periods of time, so a reliable research partner is essential. For the price that you have charged the quality of your services were exceptional. We look forward to continue our relationship with your team on future engagements....

This is with regards to your report on India PVC pipes and fitting market outlook industry outlook to 2019. This is a very well written report and accept my compliments on the same.... ...

I am pleased to see the very useful and productive information in the report..Very well structured great presentation reflect professionalism in your research studies....

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ...

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!...



Related Products in vertical
Ken Research Pvt. Ltd. Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India

download

Company Brochure

Engage with Us

query [@] kenresearch.com